The global heparin market size is estimated to grow by USD 3,009.44 millionfrom 2022 to 2027, according to Technavio. The market is estimated to grow at a CAGR of 6.94% during the forecast period. Europe will account for 39% of the global market growth. The rising prevalence of obesity and smoking and the high consumption of alcohol will drive the growth of the heparin market in the region during the forecast period. The UK, Germany, and France are the key countries for the heparin market in Europe. Moreover, market growth in this region will be faster than the growth of other regions. For more insights on the historic period (2017 to 2021) and forecast market size (2023 to 2027) – Request a sample report
What’s New?
- Special coverage on the Russia-Ukraine war; global inflation; recovery analysis from COVID-19; supply chain disruptions, global trade tensions; and risk of recession
- Global competitiveness and key competitor positions
- Market presence across multiple geographical footprints – Strong/Active/Niche/Trivial – buy the report!
Heparin Market – Segmentation Assessment
Segment Overview
This report extensively covers market segmentation by product (low-molecular-weight heparin and others), route of administration (subcutaneous injection and intravenous/infusion), and geography (Europe, North America, Asia, and Rest of World (ROW)).
- The low-molecular-weight heparin segment will be significant for market growth during the forecast period. The adoption of low-molecular-weight heparin products is expected to grow during the forecast period owing to their advantages and efficacy and wide availability. It acts by inhibiting the coagulation mechanism in the blood. It converts fibrinogen into fibrin through the activity of thrombin. Hence, due to the wide availability of low-molecular-weight heparin products and their advantages and efficacy, their adoption is expected to grow during the forecast period.
Insights on the market contribution of various segments including country and region wise, historic market data (2017 to 2021), and forecast market size (2023 to 2027) – Download a Sample Report
Heparin Market – Market Dynamics
Key factor driving market growth
The growing prevalence of chronic conditions is a major factor driving the market growth. The increasing prevalence of coagulation disorders is driving the growth of the heparin market. Some of the common coagulation disorders include Von Willebrand disease, hemophilia, deep venous thrombosis, hypercoagulable states, and clotting factor deficiencies. The increasing prevalence of these coagulation disorders needs continuous monitoring for further medical interventions. Furthermore, physicians recommend coagulation tests during major surgeries.
Leading trends influencing the market- The advent of biosimilar low-molecular-weight heparin is an emerging trend in the market.
Major challenges hindering the market growth- The side effects of heparin will challenge the growth of the heparin market. Insights on Market Drivers, trends, & Challenges, historic period(2017 to 2021), and forecast period(2023 to 2027)- Request a sample report!
What are the key data covered in this Heparin Market report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the heparin market between 2023 and 2027
- Precise estimation of the size of the heparin market size and its contribution to the market in focus on the parent market
- Accurate predictions about upcoming trends and changes in consumer behavior
- Growth of the heparin market industry across Europe, North America, Asia, and Rest of World (ROW)
- A thorough analysis of the market’s competitive landscape and detailed information about vendors
- Comprehensive analysis of factors that will challenge the growth of heparin market vendors
Gain instant access to 17,000+ market research reports.
Technavio’s SUBSCRIPTION platform
Related Reports:
The anti-thrombin III testing market size is expected to increase to USD 161.48 million from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 7.73%. Furthermore, this report extensively covers anti-thrombin III testing market segmentation by end-user (hospitals, laboratories, and academic and research institutes) and geography (North America, Europe, Asia, and Rest of World (ROW)). The existence of tests related to anti-thrombin III is notably driving the anti-thrombin III testing market growth.
The anticoagulant reversal drugs market size is expected to increase by USD 877.37 million from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 12.27%. Furthermore, this report extensively covers anticoagulant reversal drugs market segmentation by distribution channel (hospital pharmacy, retail pharmacy, and online pharmacy) and geography (North America, Europe, Asia, and Rest of World (ROW)). The increasing prevalence of coagulation disorders is notably driving the anticoagulant reversal drugs market growth.
| Heparin Market Scope | |
| Report Coverage | Details |
| Base year | 2022 |
| Historic period | 2017-2021 |
| Forecast period | 2023-2027 |
| Growth momentum & CAGR | Accelerate at a CAGR of 6.94% |
| Market growth 2023-2027 | USD 3,009.44 million |
| Market structure | Fragmented |
| YoY growth 2022-2023 (%) | 6.41 |
| Regional analysis | Europe, North America, Asia, and Rest of World (ROW) |
| Performing market contribution | Europe at 39% |
| Key countries | US, UK, Germany, France, and China, Canada, Mexico, Italy,Spain, India, Japan, Australia, and South Korea |
| Competitive landscape | Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
| Key companies profiled | Aspen Pharmacare Holdings, B. Braun SE, Baxter International Inc., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Fresenius SE and Co. KGaA, Hebei Changshan Biochemical, Hikma Pharmaceuticals Plc, Laboratorios Farmaceuticos Rovi, LEO Pharma AS, Nanjing Kingfriend Biochemical, Nichi Iko Pharmaceutical Co. Ltd., Novartis AG, Opocrin SpA, Pfizer Inc., Sanofi SA, Shanghai Fosun Pharmaceutical Group Co. Ltd., Shenzhen Techdow Pharmaceutical, Teva Pharmaceutical Industries Ltd., and Viatris Inc. |
| Market dynamics | Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period. |
| Customization purview | If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Table of Contents
1 Executive Summary
- 1.1 Market Overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Route of Administration
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 13: Market segments
- 3.3 Market size 2022
- 3.4 Market outlook: Forecast for 2022-2027
- Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
- Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
- 4.1 Global heparin market 2017 – 2021
- Exhibit 18: Historic Market Size – Data Table on Global heparin market 2017 – 2021 ($ million)
- 4.2 Product Segment Analysis 2017 – 2021
- Exhibit 19: Historic Market Size – Product Segment 2017 – 2021 ($ million)
- 4.3 Route of administration Segment Analysis 2017 – 2021
- Exhibit 20: Historic Market Size – Route of administration Segment 2017 – 2021 ($ million)
- 4.4 Geography Segment Analysis 2017 – 2021
- Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
- 4.5 Country Segment Analysis 2017 – 2021
- Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
5 Five Forces Analysis
- 5.1 Five forces summary
- Exhibit 23: Five forces analysis – Comparison between2022 and 2027
- 5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
- 5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
- 5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
- 5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
- 5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
- 5.7 Market condition
- Exhibit 29: Chart on Market condition – Five forces 2022 and 2027
6 Market Segmentation by Product
- 6.1 Market segments
- Exhibit 30: Chart on Product – Market share 2022-2027 (%)
- Exhibit 31: Data Table on Product – Market share 2022-2027 (%)
- 6.2 Comparison by Product
- Exhibit 32: Chart on Comparison by Product
- Exhibit 33: Data Table on Comparison by Product
- 6.3 Low-molecular-weight heparin – Market size and forecast 2022-2027
- Exhibit 34: Chart on Low-molecular-weight heparin – Market size and forecast 2022-2027 ($ million)
- Exhibit 35: Data Table on Low-molecular-weight heparin – Market size and forecast 2022-2027 ($ million)
- Exhibit 36: Chart on Low-molecular-weight heparin – Year-over-year growth 2022-2027 (%)
- Exhibit 37: Data Table on Low-molecular-weight heparin – Year-over-year growth 2022-2027 (%)
- 6.4 Others – Market size and forecast 2022-2027
- Exhibit 38: Chart on Others – Market size and forecast 2022-2027 ($ million)
- Exhibit 39: Data Table on Others – Market size and forecast 2022-2027 ($ million)
- Exhibit 40: Chart on Others – Year-over-year growth 2022-2027 (%)
- Exhibit 41: Data Table on Others – Year-over-year growth 2022-2027 (%)
- 6.5 Market opportunity by Product
- Exhibit 42: Market opportunity by Product ($ million)
7 Market Segmentation by Route of Administration
- 7.1 Market segments
- Exhibit 43: Chart on Route of Administration – Market share 2022-2027 (%)
- Exhibit 44: Data Table on Route of Administration – Market share 2022-2027 (%)
- 7.2 Comparison by Route of Administration
- Exhibit 45: Chart on Comparison by Route of Administration
- Exhibit 46: Data Table on Comparison by Route of Administration
- 7.3 Subcutaneous injection – Market size and forecast 2022-2027
- Exhibit 47: Chart on Subcutaneous injection – Market size and forecast 2022-2027 ($ million)
- Exhibit 48: Data Table on Subcutaneous injection – Market size and forecast 2022-2027 ($ million)
- Exhibit 49: Chart on Subcutaneous injection – Year-over-year growth 2022-2027 (%)
- Exhibit 50: Data Table on Subcutaneous injection – Year-over-year growth 2022-2027 (%)
- 7.4 Intravenous/infusion – Market size and forecast 2022-2027
- Exhibit 51: Chart on Intravenous/infusion – Market size and forecast 2022-2027 ($ million)
- Exhibit 52: Data Table on Intravenous/infusion – Market size and forecast 2022-2027 ($ million)
- Exhibit 53: Chart on Intravenous/infusion – Year-over-year growth 2022-2027 (%)
- Exhibit 54: Data Table on Intravenous/infusion – Year-over-year growth 2022-2027 (%)
- 7.5 Market opportunity by Route of Administration
- Exhibit 55: Market opportunity by Route of Administration ($ million)
8 Customer Landscape
- 8.1 Customer landscape overview
- Exhibit 56: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
- 9.1 Geographic segmentation
- Exhibit 57: Chart on Market share by geography 2022-2027 (%)
- Exhibit 58: Data Table on Market share by geography 2022-2027 (%)
- 9.2 Geographic comparison
- Exhibit 59: Chart on Geographic comparison
- Exhibit 60: Data Table on Geographic comparison
- 9.3 Europe – Market size and forecast 2022-2027
- Exhibit 61: Chart on Europe – Market size and forecast 2022-2027 ($ million)
- Exhibit 62: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
- Exhibit 63: Chart on Europe – Year-over-year growth 2022-2027 (%)
- Exhibit 64: Data Table on Europe – Year-over-year growth 2022-2027 (%)
- 9.4 North America – Market size and forecast 2022-2027
- Exhibit 65: Chart on North America – Market size and forecast 2022-2027 ($ million)
- Exhibit 66: Data Table on North America – Market size and forecast 2022-2027 ($ million)
- Exhibit 67: Chart on North America – Year-over-year growth 2022-2027 (%)
- Exhibit 68: Data Table on North America – Year-over-year growth 2022-2027 (%)
- 9.5 Asia – Market size and forecast 2022-2027
- Exhibit 69: Chart on Asia – Market size and forecast 2022-2027 ($ million)
- Exhibit 70: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
- Exhibit 71: Chart on Asia – Year-over-year growth 2022-2027 (%)
- Exhibit 72: Data Table on Asia – Year-over-year growth 2022-2027 (%)
- 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
- Exhibit 73: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
- Exhibit 74: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
- Exhibit 75: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
- Exhibit 76: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
- 9.7 US – Market size and forecast 2022-2027
- Exhibit 77: Chart on US – Market size and forecast 2022-2027 ($ million)
- Exhibit 78: Data Table on US – Market size and forecast 2022-2027 ($ million)
- Exhibit 79: Chart on US – Year-over-year growth 2022-2027 (%)
- Exhibit 80: Data Table on US – Year-over-year growth 2022-2027 (%)
- 9.8 UK – Market size and forecast 2022-2027
- Exhibit 81: Chart on UK – Market size and forecast 2022-2027 ($ million)
- Exhibit 82: Data Table on UK – Market size and forecast 2022-2027 ($ million)
- Exhibit 83: Chart on UK – Year-over-year growth 2022-2027 (%)
- Exhibit 84: Data Table on UK – Year-over-year growth 2022-2027 (%)
- 9.9 Germany – Market size and forecast 2022-2027
- Exhibit 85: Chart on Germany – Market size and forecast 2022-2027 ($ million)
- Exhibit 86: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
- Exhibit 87: Chart on Germany – Year-over-year growth 2022-2027 (%)
- Exhibit 88: Data Table on Germany – Year-over-year growth 2022-2027 (%)
- 9.10 China – Market size and forecast 2022-2027
- Exhibit 89: Chart on China – Market size and forecast 2022-2027 ($ million)
- Exhibit 90: Data Table on China – Market size and forecast 2022-2027 ($ million)
- Exhibit 91: Chart on China – Year-over-year growth 2022-2027 (%)
- Exhibit 92: Data Table on China – Year-over-year growth 2022-2027 (%)
- 9.11 France – Market size and forecast 2022-2027
- Exhibit 93: Chart on France – Market size and forecast 2022-2027 ($ million)
- Exhibit 94: Data Table on France – Market size and forecast 2022-2027 ($ million)
- Exhibit 95: Chart on France – Year-over-year growth 2022-2027 (%)
- Exhibit 96: Data Table on France – Year-over-year growth 2022-2027 (%)
- 9.12 Market opportunity by geography
- Exhibit 97: Market opportunity by geography ($ million)
10 Drivers, Challenges, and Trends
- 10.1 Market drivers
- 10.2 Market challenges
- 10.3 Impact of drivers and challenges
- Exhibit 98: Impact of drivers and challenges in 2022 and 2027
- 10.4 Market trends
11 Vendor Landscape
- 11.1 Overview
- 11.2 Vendor landscape
- Exhibit 99: Overview on Criticality of inputs and Factors of differentiation
- 11.3 Landscape disruption
- Exhibit 100: Overview on factors of disruption
- 11.4 Industry risks
- Exhibit 101: Impact of key risks on business
12 Vendor Analysis
- 12.1 Vendors covered
- Exhibit 102: Vendors covered
- 12.2 Market positioning of vendors
- Exhibit 103: Matrix on vendor position and classification
- 12.3 Aspen Pharmacare Holdings
- Exhibit 104: Aspen Pharmacare Holdings – Overview
- Exhibit 105: Aspen Pharmacare Holdings – Business segments
- Exhibit 106: Aspen Pharmacare Holdings – Key offerings
- Exhibit 107: Aspen Pharmacare Holdings – Segment focus
- 12.4 B. Braun SE
- Exhibit 108: B. Braun SE – Overview
- Exhibit 109: B. Braun SE – Business segments
- Exhibit 110: B. Braun SE – Key news
- Exhibit 111: B. Braun SE – Key offerings
- Exhibit 112: B. Braun SE – Segment focus
- 12.5 Baxter International Inc.
- Exhibit 113: Baxter International Inc. – Overview
- Exhibit 114: Baxter International Inc. – Business segments
- Exhibit 115: Baxter International Inc. – Key news
- Exhibit 116: Baxter International Inc. – Key offerings
- Exhibit 117: Baxter International Inc. – Segment focus
- 12.6 Eisai Co. Ltd.
- Exhibit 118: Eisai Co. Ltd. – Overview
- Exhibit 119: Eisai Co. Ltd. – Business segments
- Exhibit 120: Eisai Co. Ltd. – Key offerings
- Exhibit 121: Eisai Co. Ltd. – Segment focus
- 12.7 Fresenius SE and Co. KGaA
- Exhibit 122: Fresenius SE and Co. KGaA – Overview
- Exhibit 123: Fresenius SE and Co. KGaA – Business segments
- Exhibit 124: Fresenius SE and Co. KGaA – Key news
- Exhibit 125: Fresenius SE and Co. KGaA – Key offerings
- Exhibit 126: Fresenius SE and Co. KGaA – Segment focus
- 12.8 Hikma Pharmaceuticals Plc
- Exhibit 127: Hikma Pharmaceuticals Plc – Overview
- Exhibit 128: Hikma Pharmaceuticals Plc – Business segments
- Exhibit 129: Hikma Pharmaceuticals Plc – Key offerings
- Exhibit 130: Hikma Pharmaceuticals Plc – Segment focus
- 12.9 Laboratorios Farmaceuticos Rovi
- Exhibit 131: Laboratorios Farmaceuticos Rovi – Overview
- Exhibit 132: Laboratorios Farmaceuticos Rovi – Business segments
- Exhibit 133: Laboratorios Farmaceuticos Rovi – Key offerings
- Exhibit 134: Laboratorios Farmaceuticos Rovi – Segment focus
- 12.10 Nanjing Kingfriend Biochemical
- Exhibit 135: Nanjing Kingfriend Biochemical – Overview
- Exhibit 136: Nanjing Kingfriend Biochemical – Product / Service
- Exhibit 137: Nanjing Kingfriend Biochemical – Key offerings
- 12.11 Nichi Iko Pharmaceutical Co. Ltd.
- Exhibit 138: Nichi Iko Pharmaceutical Co. Ltd. – Overview
- Exhibit 139: Nichi Iko Pharmaceutical Co. Ltd. – Product / Service
- Exhibit 140: Nichi Iko Pharmaceutical Co. Ltd. – Key offerings
- 12.12 Novartis AG
- Exhibit 141: Novartis AG – Overview
- Exhibit 142: Novartis AG – Business segments
- Exhibit 143: Novartis AG – Key offerings
- Exhibit 144: Novartis AG – Segment focus
- 12.13 Pfizer Inc.
- Exhibit 145: Pfizer Inc. – Overview
- Exhibit 146: Pfizer Inc. – Product / Service
- Exhibit 147: Pfizer Inc. – Key news
- Exhibit 148: Pfizer Inc. – Key offerings
- 12.14 Sanofi SA
- Exhibit 149: Sanofi SA – Overview
- Exhibit 150: Sanofi SA – Business segments
- Exhibit 151: Sanofi SA – Key news
- Exhibit 152: Sanofi SA – Key offerings
- Exhibit 153: Sanofi SA – Segment focus
- 12.15 Shenzhen Techdow Pharmaceutical
- Exhibit 154: Shenzhen Techdow Pharmaceutical – Overview
- Exhibit 155: Shenzhen Techdow Pharmaceutical – Product / Service
- Exhibit 156: Shenzhen Techdow Pharmaceutical – Key offerings
- 12.16 Teva Pharmaceutical Industries Ltd.
- Exhibit 157: Teva Pharmaceutical Industries Ltd. – Overview
- Exhibit 158: Teva Pharmaceutical Industries Ltd. – Business segments
- Exhibit 159: Teva Pharmaceutical Industries Ltd. – Key news
- Exhibit 160: Teva Pharmaceutical Industries Ltd. – Key offerings
- Exhibit 161: Teva Pharmaceutical Industries Ltd. – Segment focus
- 12.17 Viatris Inc.
- Exhibit 162: Viatris Inc. – Overview
- Exhibit 163: Viatris Inc. – Business segments
- Exhibit 164: Viatris Inc. – Key offerings
- Exhibit 165: Viatris Inc. – Segment focus
13 Appendix
- 13.1 Scope of the report
- 13.2 Inclusions and exclusions checklist
- Exhibit 166: Inclusions checklist
- Exhibit 167: Exclusions checklist
- 13.3 Currency conversion rates for US$
- Exhibit 168: Currency conversion rates for US$
- 13.4 Research methodology
- Exhibit 169: Research methodology
- Exhibit 170: Validation techniques employed for market sizing
- Exhibit 171: Information sources
- 13.5 List of abbreviations
- Exhibit 172: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com
SOURCE Technavio